India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
November marked another cooldown for commercial real estate, with total deal volume dropping 10% year over year and falling below even 2020’s levels. While overall activity is slowing, investors are concentrating their money on bigger, more resilient assets—driving a 51% surge in deals over $100 million and pushing average transaction sizes well above historical norms. Multifamily remains the strongest sector, office deals are becoming more strategically focused, and medical office and data centers continue to outperform as long‑term demand stays solid.
After years of stalled activity, commercial real estate may finally be nearing a rebound. Experts say that expected interest‑rate drops in 2026 could reignite investor confidence, unlock sidelined capital, and boost deal flow across multiple sectors. But the outlook isn’t uniformly sunny—multifamily faces oversupply, industrial is cooling after years of rapid growth, and weakening employment conditions may slow absorption. For professionals across real estate, mortgage, insurance, and finance, the shifting landscape presents both challenges and major opportunities for those who stay informed and properly licensed.
Consumer Reports delivered a major warning to Congress, highlighting how rapidly expanding fintech tools—especially AI‑driven platforms—are outpacing consumer protections. In testimony before the House Subcommittee on Digital Assets, Financial Technology and AI, CR called for stronger, clearer rules to prevent hidden fees, predatory practices, and confusion within digital financial products. For professionals in real estate, mortgages, insurance, and finance, these emerging regulations may soon influence lending decisions, underwriting, credit evaluations, and compliance expectations across the industry.
Amazon is preparing to cut up to 30,000 corporate jobs by mid‑2026 as it pivots aggressively toward automation and AI. Following 14,000 layoffs in late 2025, the company is eliminating layers of management to redirect billions into robotics, generative AI systems, and supercomputing partnerships. While warehouse hiring continues for seasonal demand, Amazon’s internal shift reveals a broader nationwide trend: white‑collar roles across tech, finance, logistics, and more are being reshaped by automation at unprecedented speed.
Florida’s real estate market enters 2026 with new leadership at the helm as Chuck Bonfiglio, broker-owner of AAA Realty Group, is officially installed as President of Florida Realtors. With more than 230,000 members behind the association, Bonfiglio highlights affordability, insurance reform, and taxes as key priorities while expressing optimism about easing mortgage rates, stabilizing prices, and growing inventory. Backed by years of statewide and national Realtor leadership, he aims to guide professionals through another transformative year alongside a newly appointed 2026 leadership team.
Tampa isn’t cooling off—it’s getting smarter. After years of rapid expansion, the city’s commercial real estate market has shifted into a more disciplined, selective phase. Population growth remains strong, office leasing is outperforming national trends, industrial activity is normalizing sustainably, and retail is seeing renewed investor confidence. With capital becoming more cautious and health care real estate emerging as a major growth sector, Tampa is entering a new era focused on strategy, execution, and long‑term fundamentals.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
